Cybin Inc. (CYBN)
AMEX: CYBN
· Real-Time Price · USD
6.48
-0.14 (-2.11%)
At close: May 02, 2025, 3:59 PM
6.50
0.31%
After-hours: May 02, 2025, 04:49 PM EDT
-2.11% (1D)
| Bid | 6.48 |
| Market Cap | 136.25M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -103.9M |
| EPS (ttm) | -3.59 |
| PE Ratio (ttm) | -1.81 |
| Forward PE | -1.61 |
| Analyst | Buy |
| Ask | 6.9 |
| Volume | 151,362 |
| Avg. Volume (20D) | 296,601 |
| Open | 6.79 |
| Previous Close | 6.62 |
| Day's Range | 6.46 - 6.85 |
| 52-Week Range | 4.81 - 14.44 |
| Beta | 1.09 |
About CYBN
Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a phenethylamine derivative to treat neuroinflammation. It has also developed EMBARK, a psychedelic-assisted psychotherapy. The company...
Industry Biotechnology
Sector Healthcare
IPO Date Sep 13, 2019
Employees 50
Stock Exchange AMEX
Ticker Symbol CYBN
Website https://www.cybin.com
Analyst Forecast
According to 4 analyst ratings, the average rating for CYBN stock is "Buy." The 12-month stock price forecast is $73, which is an increase of 1026.54% from the latest price.
Stock Forecasts11 months ago
-9.67%
Shares of psychedelics companies are trading lower...
Unlock content with
Pro Subscription
